Malignant Hyperthermia Panel
The Malignant Hyperthermia Panel includes four tests, run STAT.
Please see the individual tests for information:
- Critical Care Panel I
- Complete Blood Count
- Protime and aPTT
All specimens must be sent TOGETHER, immediately after collection, to the STAT Laboratory (Royal Oak), Chemistry Laboratory (Troy) or Chemistry Laboratory (Farmington Hills).
- The Malignant Hyperthermia Panel is part of a protocol used to facilitate a rapid response to patients in which Malignant Hyperthermia is suspected.
- Malignant Hyperthermia (MH) is a potentially life-threatening disorder that is triggered by the administration of certain anesthetic agents such as injectable succinylcholine or inhaled volatile agents (i.e. halothane, sevoflurane, desflurane, isoflurane) in genetically susceptible individuals. It is thought to be due to a defect in calcium handling leading to hyperkalemia and rhabdomyolysis. The incidence ranges from 1:5,000 to 1:50,000-100,000. The reaction is characterized by:
- a rapid rise in end-tidal CO2 (earliest sign)
- jaw muscle spasm or rigidity (early sign in many patients)
- trunk or whole body rigidity (not always present)
- respiratory and metabolic acidosis
- a marked elevation in temperature (typically a late sign) rhabdomyolysis.
- MH can occur intra-operatively or up to 4-12 hours post-operatively. The mortality is approximately 80% if unrecognized and untreated, but decreases to less than 5% with early recognition and treatment.
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.
This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills,
Grosse Pointe, Royal Oak, and Troy campuses.